14756-77-5

Basic information

• Product Name: 3-Amino-1,5-naphthyridine
• Synonyms: 3-Amino-1,5-naphthyridine;1,5-naphthyridin-3-amine
• CAS NO: 14756-77-5
• Molecular Formula: C8H7N3
• Molecular Weight: 145.17
• Mol File: 14756-77-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 144-145 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 329.7±22.0 °C(Predicted)
• Appearance: /
• Density: 1.292±0.06 g/cm3(Predicted)
• PKA: 3.08±0.10(Predicted)
• CAS DataBase Reference: 3-Amino-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-1,5-naphthyridine(14756-77-5)
• EPA Substance Registry System: 3-Amino-1,5-naphthyridine(14756-77-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 14756-77-5(Hazardous Substances Data)

Usage

General Description

3-Amino-1,5-naphthyridine is a chemical compound that is often utilized in fields like pharmaceuticals and materials science. This pale yellow crystalline compound is known for its capability to act as a building block in the synthesis of several bioactive molecules. It belongs to the group of naphthyridines, which are heterocyclic compounds composed of two condensed pyridine rings. Its structural similarity to purine has seen its derivatives exhibit antitumor, anticancer, and anti-inflammatory activities in biomedical research. Due to its potential importance in medical applications, the methods of synthesizing 3-Amino-1,5-naphthyridine have attracted considerable interest.

Upstream product

• 17965-71-8 3-bromo-1,5-naphthyridine 
• 254-79-5 1,5-naphthyridine 
• 64222-33-9 3-nitro-1H-[1,5]naphthyridin-2-one 
• 67-56-1 methanol 
• 74919-33-8 2-chloro-3-nitro-1,5-naphthyridine 
• 959617-73-3 tert-butyl (1,5-naphthyridin-3-yl)carbamate 

Downstream Products

• 959617-74-4 3-fluoro-1,5-naphthyridine 

Relevant articles and documents

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.